Optein, Inc.
Records under this name other than the patents Optein, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 8 of 8 · Back to Optein, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,383,780 | Antibodies to Tgf-Beta Term ended Term ended Feb 8, 2026 · High confidence | Term ended | Term ended Feb 8, 2026 | High confidence |
| US 8,591,901 | Antibodies to Tgf-Beta Term ended Term ended Feb 8, 2026 · High confidence | Term ended | Term ended Feb 8, 2026 | High confidence |
| US 9,090,685 | Antibodies to Tgf-Beta Term ended Term ended Feb 8, 2026 · High confidence | Term ended | Term ended Feb 8, 2026 | High confidence |
| US 10,174,108 | Antibodies to Tgf-Beta Term ended Term ended Feb 8, 2026 · Medium confidence | Term ended | Term ended Feb 8, 2026 | Medium confidence |
| US 10,781,252 | Antibodies to TGF-Beta Term ended Term ended Feb 8, 2026 · High confidence | Term ended | Term ended Feb 8, 2026 | High confidence |
| US 12,612,453 | Method of Treating Glomerulonephritis by Administering an Antibody Which Binds and Neutralizes Human TGF-BETA1, TGF-BETA2 and TGF-BETA3 Term ended Term ended Feb 8, 2026 · Medium confidence | Term ended | Term ended Feb 8, 2026 | Medium confidence |
| US 5,643,768 | Cell-free synthesis and isolation of novel genes and polypeptides Term ended Term ended no later than Jul 1, 2017 · Low confidence | Term ended | Term ended no later than Jul 1, 2017 | Low confidence |
| US 5,658,754 | Cell-free synthesis and isolation of novel genes and polypeptides Term ended Term ended no later than Aug 19, 2017 · Low confidence | Term ended | Term ended no later than Aug 19, 2017 | Low confidence |